Dr. Wistinghausen Discusses Targeted Therapies for Pediatric NHL

Birte Wistinghausen, MD
Published: Thursday, May 31, 2018



Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma (NHL).

The Children’s Oncology Group is currently conducting trials with targeted therapies in the frontline setting. ANHL1131 is a phase II/III trial evaluating the safety and efficacy of rituximab (Rituxan) in children or adolescents with higher-risk NHL. These are patients with B-cell lymphoma or B-cell leukemia, says Wistinghausen.

There is also an open study evaluating chemotherapy in combination with brentuximab vedotin (Adcetris) or crizotinib (Xalkori) in patients with newly diagnosed stage III/IV anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an anti-CD30 antibody, and ALCL expresses CD30, says Wistinghausen. Crizotinib is an ALK inhibitor, and more than 95% of pediatric patients with ALCL are ALK-positive. The study, ANHL12P1, is currently recruiting for the crizotinib arm.
SELECTED
LANGUAGE


Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma (NHL).

The Children’s Oncology Group is currently conducting trials with targeted therapies in the frontline setting. ANHL1131 is a phase II/III trial evaluating the safety and efficacy of rituximab (Rituxan) in children or adolescents with higher-risk NHL. These are patients with B-cell lymphoma or B-cell leukemia, says Wistinghausen.

There is also an open study evaluating chemotherapy in combination with brentuximab vedotin (Adcetris) or crizotinib (Xalkori) in patients with newly diagnosed stage III/IV anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an anti-CD30 antibody, and ALCL expresses CD30, says Wistinghausen. Crizotinib is an ALK inhibitor, and more than 95% of pediatric patients with ALCL are ALK-positive. The study, ANHL12P1, is currently recruiting for the crizotinib arm.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x